Patents by Inventor Sébastien Laurent Xavier Martina

Sébastien Laurent Xavier Martina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210169879
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFN?, IL12 and/or IL23 by administering the compound of the invention.
    Type: Application
    Filed: October 11, 2018
    Publication date: June 10, 2021
    Inventors: Steven Emiel VAN DER PLAS, Oscar MAMMOLITI, Sébastien Laurent Xavier MARTINA, Pieter Isabelle Roger CLAES, Ghjuvanni Petru Diunisu COTI, Denis Maurice ANNOOT, Miriam LÓPEZ RAMOS, René Alexandre GALIEN, David AMANTINI, Reginald Christophe Xavier BRYS
  • Patent number: 10568867
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 25, 2020
    Assignee: GALAPAGOS NV
    Inventors: Steven Emiel Van der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Patent number: 10047051
    Abstract: The invention discloses compounds of Formula I wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 14, 2018
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Marlon D. Cowart, Tom Roger Lisette De Munck, Sébastien Jean Jacques Cédric Dropsit Montovert, Gregory A. Gfesser, Hans Kelgtermans, Sébastien Laurent Xavier Martina, Steven Emiel Van der Plas, Xueqing Wang
  • Publication number: 20180221334
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 9, 2018
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVERT, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Patent number: 9895347
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: February 20, 2018
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Publication number: 20160355480
    Abstract: The invention discloses compounds of Formula I wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 8, 2016
    Inventors: Robert J. Altenbach, Marlon D. Cowart, Tom Roger Lisette De Munck, Sébastien Jean Jacques Cédric Dropsit Montovert, Gregory A. Gfesser, Hans Kelgtermans, Sébastien Laurent Xavier Martina, Steven Emiel Van der Plas, Xueqing Wang
  • Publication number: 20160317493
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 2, 2016
    Publication date: November 3, 2016
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVERT, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Patent number: 9351955
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: May 31, 2016
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Publication number: 20160022633
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVERT, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Patent number: 9133210
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: September 15, 2015
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Publication number: 20150045327
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 12, 2015
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVER, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Publication number: 20120010206
    Abstract: Novel imidazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Application
    Filed: May 25, 2011
    Publication date: January 12, 2012
    Inventors: Paul John EDWARDS, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS, Grégory Louis Joseph BAR, Brigitte ALLART, Andrew BURRITT, Xueliang TAO, Friedrich Erich Karl KROLL
  • Patent number: 7977352
    Abstract: Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 12, 2011
    Assignee: Galapagos NV
    Inventors: Paul John Edwards, Wolfgang Schmidt, Veronique Birault, Friedrich Erich Karl Kroll, Andrew Burritt, Xueliang Tao, Martin James Inglis Andrews, Sébastien Laurent Xavier Martina
  • Patent number: 7951818
    Abstract: Novel imidazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: May 31, 2011
    Assignee: Galapagos NV
    Inventors: Paul John Edwards, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews, Grégory Louis Joseph Bar, Brigitte Allart, Andrew Burritt, Xueliang Tao, Friedrich Erich Karl Kroll
  • Publication number: 20090105242
    Abstract: Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Application
    Filed: November 30, 2007
    Publication date: April 23, 2009
    Inventors: Paul John Edwards, Wolfgang Schmidt, Veronique Birault, Friedrich Erich Karl Kroll, Andrew Burritt, Xueliang Tao, Martin James Inglis Andrews, Sebastien Laurent Xavier Martina
  • Publication number: 20090048245
    Abstract: Novel imidazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Application
    Filed: November 30, 2007
    Publication date: February 19, 2009
    Inventors: Paul John Edwards, Sebastien Laurent Xavier Martina, Martin James Inglis Andrews, Gregory Louis Joseph Bar, Brigitte Allart, Andrew Burritt, Xueliang Tao, Friedrich Erich Karl Kroll